Blueprint Medicines CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Blueprint Medicines' FY2024 10-K filing details the company's financial performance, strategic focus on allergy/inflammation and oncology/hematology, and pipeline advancements.
Blueprint Medicines Corporation released its annual financial report, detailing advancements in its oncology and mast cell-mediated disease treatment pipeline, including progress with AYVAKIT/AYVAKYT and other investigational therapies.